Elham Samadi1, Hessam Mirshahabi1, Nima Motamed2, Hamid Sadeghi1. 1. Department of Microbiology and Virology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. 2. Department of Social Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Abstract
BACKGROUND: Occult hepatitis B infection (OBI) is defined as the lack of detectable HBsAg in serum, despite the presence of intrahepatic viral DNA, and low levels of covalently closed circular DNA (cccDNA). Since the hemodialysis patients are at a greater disadvantage if they are a carrier of Hep B, as it can lead to OBI this study was designed to determine the prevalence of OBI in hemodialysis patients residing in Zanjan, Iran. METHODS: We conducted an anti-HBc test (ELISA) on 166 HBsAg negative hemodialysis patient samples. OBI was evaluated using seropositive (anti-HBc and/or anti-HBs) and seronegative (anti-HBc and anti-HBs) using nested PCR. RESULTS: Out of the total hemodialysis patients sampled, the study consisted of 58.4% male and 41.6% female participants. The age of the study group ranged from 58.89±15.49, and had received approximately 28.27±27.43 years of dialysis. Additionally, 5.4% of patients had a history of blood transfusions, while 58.4% were vaccinated against the hepatitis B virus (HBV). Moreover, 23.5% patients were anti-HBc positive, while 76.5% patients tested negative. Lastly, 66.3% of the patients were positive for anti-HBs, whereas 33.7% were negative for anti-HBs. Overall, the study revealed that the prevalence of OBI was 6%, and HBV DNA was detected in 2.1% of individuals who were vaccinated against hepatitis B (p < 0.01). CONCLUSION: Though no significant difference between the prevalence of OBI to the patients' age, sex, duration of dialysis, or history of blood transfusion was identified, however, a strong correlation between the prevalence of OBI to HBV vaccination was found.
BACKGROUND: Occult hepatitis B infection (OBI) is defined as the lack of detectable HBsAg in serum, despite the presence of intrahepatic viral DNA, and low levels of covalently closed circular DNA (cccDNA). Since the hemodialysis patients are at a greater disadvantage if they are a carrier of Hep B, as it can lead to OBI this study was designed to determine the prevalence of OBI in hemodialysis patients residing in Zanjan, Iran. METHODS: We conducted an anti-HBc test (ELISA) on 166 HBsAg negative hemodialysis patient samples. OBI was evaluated using seropositive (anti-HBc and/or anti-HBs) and seronegative (anti-HBc and anti-HBs) using nested PCR. RESULTS: Out of the total hemodialysis patients sampled, the study consisted of 58.4% male and 41.6% female participants. The age of the study group ranged from 58.89±15.49, and had received approximately 28.27±27.43 years of dialysis. Additionally, 5.4% of patients had a history of blood transfusions, while 58.4% were vaccinated against the hepatitis B virus (HBV). Moreover, 23.5% patients were anti-HBc positive, while 76.5% patients tested negative. Lastly, 66.3% of the patients were positive for anti-HBs, whereas 33.7% were negative for anti-HBs. Overall, the study revealed that the prevalence of OBI was 6%, and HBV DNA was detected in 2.1% of individuals who were vaccinated against hepatitis B (p < 0.01). CONCLUSION: Though no significant difference between the prevalence of OBI to the patients' age, sex, duration of dialysis, or history of blood transfusion was identified, however, a strong correlation between the prevalence of OBI to HBV vaccination was found.
Entities:
Keywords:
ELISA; Hemodialysis; Nested PCR; Occult hepatitis B infection
Authors: Giovanni Raimondo; Jean-Pierre Allain; Maurizia R Brunetto; Marie-Annick Buendia; Ding-Shinn Chen; Massimo Colombo; Antonio Craxì; Francesco Donato; Carlo Ferrari; Giovanni B Gaeta; Wolfram H Gerlich; Massimo Levrero; Stephen Locarnini; Thomas Michalak; Mario U Mondelli; Jean-Michel Pawlotsky; Teresa Pollicino; Daniele Prati; Massimo Puoti; Didier Samuel; Daniel Shouval; Antonina Smedile; Giovanni Squadrito; Christian Trépo; Erica Villa; Hans Will; Alessandro R Zanetti; Fabien Zoulim Journal: J Hepatol Date: 2008-07-31 Impact factor: 25.083
Authors: Andrea Martins Melo Fontenele; Juliana Braga Furtado Gainer; Daniel Viana da Silva E Silva; Max Diego Cruz Santos; João Victor Salgado; Natalino Salgado Filho; Adalgisa Sousa Paiva Ferreira Journal: Hemodial Int Date: 2015-03-02 Impact factor: 1.812
Authors: Gerald Y Minuk; Dong-Feng Sun; Julia Uhanova; Manna Zhang; Shauna Caouette; Lindsay E Nicolle; Adam Gutkin; Karen Doucette; Bruce Martin; Antonio Giulivi Journal: J Hepatol Date: 2005-01-13 Impact factor: 25.083
Authors: Jorge S Motta; Francisco C Mello; Barbara V Lago; Renata M Perez; Selma A Gomes; Fatima F Figueiredo Journal: J Gastroenterol Hepatol Date: 2009-10-09 Impact factor: 4.029